康宁杰瑞制药(09966.HK)于美国AACR年会公布两项临床前研究成果

阿斯达克财经
Apr 30, 2025

康宁杰瑞制药-B(09966.HK) 公布,JSKN021及JSKN022临床前研究的最新成果,已于今年4月25至30日举行的2025年AACR年会的壁报展示期间公布。据介绍,JSKN021是一款全球首创的双抗双载荷偶联药物,通过精确调控双抗结合亲和力设计,在应对肿瘤异质性的同时最大限度地降低靶向脱瘤毒性,具有增强的稳定性和更优的均一性;至于JSKN022是靶向PD-L1及αVβ6的全球首创多功能...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10